• Je něco špatně v tomto záznamu ?

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

P. Calzavara-Pinton, CY. Chu, H. Lapeere, M. Rossi, SM. Ferrucci, WH. Chung, AC. Fougerousse, DS. Fomina, G. Holzer, J. Čelakovská, M. Al-Ahmad, T. Tzellos, J. Wu, M. Ardeleanu, K. Bosman

. 2025 ; 42 (2) : 720-733. [pub] 20241202

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, pozorovací studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010085

INTRODUCTION: Currently, limited data are available on long-term use of dupilumab to treat atopic dermatitis (AD) in a multinational real-world setting. The aim of this analysis was to report the interim 1-year data for patients with AD enrolled in the GLOBOSTAD registry, including treatment patterns, dupilumab effectiveness and safety, and healthcare burden. METHODS: GLOBOSTAD is an ongoing, 5-year, multinational, prospective, observational study of adult/adolescent (aged ≥ 12 years at baseline) patients with AD who initiated dupilumab in real-world settings according to their local country-specific prescribing guidelines. Outcomes were evaluated at baseline and at 3, 6 and 12 months and included Eczema Area and Severity Index (EASI) total score, SCORing Atopic Dermatitis (SCORAD) total score, percent body surface area (BSA) affected, Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI) total score for adults or Children's Dermatology Life Quality Index (CDLQI) total score for adolescents and pruritus Numeric Rating Scale (NRS) total score. RESULTS: At the interim 1-year cut-off (March 2023), 955 patients were enrolled in GLOBOSTAD, and follow-up data were obtained from 903 patients. After dupilumab initiation, mean improvements in effectiveness outcome measures from baseline to month 3 were EASI from 25.1 to 6.1, SCORAD 59.3 to 25.3, POEM 19.7 to 8.7, DLQI 13.7 to 5.3, CDLQI 12.2 to 2.7 and pruritus NRS 6.3 to 2.5, with each measure exceeding the minimal clinically important difference. These positive changes in effectiveness outcomes were maintained or further improved through 12 months since treatment initiation. AD-related hospitalizations and emergency room or urgent care facility visits decreased from 11.1% to 1.7% from baseline to month 12. CONCLUSIONS: In a multinational real-world setting, dupilumab demonstrated rapid, robust and sustained effectiveness in patients with moderate-to-severe AD across multiple disease domains, including AD signs, symptoms, quality of life and emergency/urgent care visits. Safety was consistent with the known dupilumab safety profile. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03992417.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010085
003      
CZ-PrNML
005      
20250429135228.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12325-024-03049-8 $2 doi
035    __
$a (PubMed)39621227
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Calzavara-Pinton, Piergiacomo $u Dermatology Department, University of Brescia, Brescia, Italy. piergiacomo.calzavarapinton@unibs.it
245    10
$a One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis / $c P. Calzavara-Pinton, CY. Chu, H. Lapeere, M. Rossi, SM. Ferrucci, WH. Chung, AC. Fougerousse, DS. Fomina, G. Holzer, J. Čelakovská, M. Al-Ahmad, T. Tzellos, J. Wu, M. Ardeleanu, K. Bosman
520    9_
$a INTRODUCTION: Currently, limited data are available on long-term use of dupilumab to treat atopic dermatitis (AD) in a multinational real-world setting. The aim of this analysis was to report the interim 1-year data for patients with AD enrolled in the GLOBOSTAD registry, including treatment patterns, dupilumab effectiveness and safety, and healthcare burden. METHODS: GLOBOSTAD is an ongoing, 5-year, multinational, prospective, observational study of adult/adolescent (aged ≥ 12 years at baseline) patients with AD who initiated dupilumab in real-world settings according to their local country-specific prescribing guidelines. Outcomes were evaluated at baseline and at 3, 6 and 12 months and included Eczema Area and Severity Index (EASI) total score, SCORing Atopic Dermatitis (SCORAD) total score, percent body surface area (BSA) affected, Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI) total score for adults or Children's Dermatology Life Quality Index (CDLQI) total score for adolescents and pruritus Numeric Rating Scale (NRS) total score. RESULTS: At the interim 1-year cut-off (March 2023), 955 patients were enrolled in GLOBOSTAD, and follow-up data were obtained from 903 patients. After dupilumab initiation, mean improvements in effectiveness outcome measures from baseline to month 3 were EASI from 25.1 to 6.1, SCORAD 59.3 to 25.3, POEM 19.7 to 8.7, DLQI 13.7 to 5.3, CDLQI 12.2 to 2.7 and pruritus NRS 6.3 to 2.5, with each measure exceeding the minimal clinically important difference. These positive changes in effectiveness outcomes were maintained or further improved through 12 months since treatment initiation. AD-related hospitalizations and emergency room or urgent care facility visits decreased from 11.1% to 1.7% from baseline to month 12. CONCLUSIONS: In a multinational real-world setting, dupilumab demonstrated rapid, robust and sustained effectiveness in patients with moderate-to-severe AD across multiple disease domains, including AD signs, symptoms, quality of life and emergency/urgent care visits. Safety was consistent with the known dupilumab safety profile. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03992417.
650    _2
$a lidé $7 D006801
650    12
$a atopická dermatitida $x farmakoterapie $7 D003876
650    12
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a prospektivní studie $7 D011446
650    _2
$a dospělí $7 D000328
650    _2
$a mladiství $7 D000293
650    _2
$a lidé středního věku $7 D008875
650    12
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a dítě $7 D002648
650    _2
$a mladý dospělý $7 D055815
650    12
$a kvalita života $7 D011788
650    _2
$a výsledek terapie $7 D016896
650    _2
$a registrace $7 D012042
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Chu, Chia-Yu $u Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan $u University College of Medicine, Taipei, Taiwan
700    1_
$a Lapeere, Hilde $u Department of Dermatology, Ghent University Hospital, Ghent, Belgium
700    1_
$a Rossi, Mariateresa $u Dermatology Department, University of Brescia, Brescia, Italy
700    1_
$a Ferrucci, Silvia M $u Unit of Dermatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
700    1_
$a Chung, Wen-Hung $u Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan
700    1_
$a Fougerousse, Anne-Claire $u Bégin Military Teaching Hospital, Saint Mandé, France $u ResoEczéma, Paris, France
700    1_
$a Fomina, Daria S $u Moscow Clinical and Research Center of Allergology and Immunology, City Clinical Hospital No 52, Moscow, Russian Federation $u I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation $u Department of Pulmonology, Astana Medical University, Astana, Kazakhstan
700    1_
$a Holzer, Gregor $u Medical University of Vienna, Vienna, Austria $u Sozialmedizinisches Zentrum Ost - Donauspital, Vienna, Austria
700    1_
$a Čelakovská, Jarmila $u Department of Dermatology and Venereology, Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, Czech Republic
700    1_
$a Al-Ahmad, Mona $u Microbiology Department, College of Medicine, Kuwait University, Kuwait City, Kuwait
700    1_
$a Tzellos, Thrasyvoulos $u Institute of Clinical Medicine, Arctic University of Norway, Tromsø, Norway
700    1_
$a Wu, Jiangming $u Sanofi, Bridgewater, NJ, USA
700    1_
$a Ardeleanu, Marius $u Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA
700    1_
$a Bosman, Kwinten $u Sanofi, Amsterdam, the Netherlands
773    0_
$w MED00179771 $t Advances in therapy $x 1865-8652 $g Roč. 42, č. 2 (2025), s. 720-733
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39621227 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135224 $b ABA008
999    __
$a ok $b bmc $g 2311445 $s 1247166
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 42 $c 2 $d 720-733 $e 20241202 $i 1865-8652 $m Advances in therapy $n Adv Ther $x MED00179771
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace